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Abstract
Background: Patients with Adult Respiratory Distress Syndrome (ARDS) and Acute Lung Injury (ALI) have low
concentrations of disaturated-phosphatidylcholine and surfactant protein-B in bronchoalveolar lavage fluid. No
information is available on their turnover.
Objectives: To analyze disaturated-phosphatidylcholine and surfactant protein-B turnover in patients with ARDS/
ALI and in human adults with normal lungs (controls).
Methods:
2H2O as precursor of disaturated-phosphatidylcholine-palmitate and 1
13C-Leucine as precursor of
surfactant protein-B were administered intravenously to 12 patients with ARDS/ALI and to 8 controls. Disaturated-
phosphatidylcholine and surfactant protein-B were isolated from serial tracheal aspirates, and their fractional
synthetic rate was derived from the
2H and
13C enrichment curves, obtained by gas chromatography mass
spectrometry. Disaturated-phosphatidylcholine, surfactant protein-B, and protein concentrations in tracheal aspirates
were also measured.
Results: 1) Surfactant protein-B turned over at faster rate than disaturated-phosphatidylcholine both in ARDS/ALI
patients and in controls. 2) In patients with ARDS/ALI the fractional synthesis rate of disaturated-
phosphatidylcholine was 3.1 times higher than in controls (p < 0.01), while the fractional synthesis rate of
surfactant protein-B was not different. 3) In ARDS/ALI patients the concentrations of disaturated-
phosphatidylcholine and surfactant protein-B in tracheal aspirates were markedly and significantly reduced (17%
and 40% of the control values respectively).
Conclusions: 1) Disaturated-phosphatidylcholine and surfactant protein-B have a different turnover both in healthy
and diseased lungs. 2) In ARDS/ALI the synthesis of these two surfactant components may be differently regulated.
Background
Adult Respiratory Distress Syndrome (ARDS) is charac-
terized by bilateral radiographic infiltrates and a ratio of
the partial pressure of arterial oxygen to the fraction of
inspired oxygen (PaO2/FiO2) <200. Acute Lung Injury
(ALI) is a less severe form of respiratory distress with a
PaO2/FiO2 between 200 and 300 [1]. In both clinical
entities reduced lung compliance and surfactant inacti-
vation contributes to the respiratory failure [2-4]. Pro-
posed mechanisms of lung injury include destruction of
the air-water interface by alveolar edema, phospholipid
degradation by secretory phospholipases, degradation of
surfactant proteins by proteases [5,6], damage by reac-
tive oxygen species and decreased synthesis of surfactant
components by damaged type II cells [7]. Moreover,
leakage of plasma proteins into the alveoli is thought to
decrease alveolar stability [8]. In vitro, proteins have
been shown to compete with the lipids for adsorption at
the air water interface, leading to the formation of an
interfacial film less prone to incorporate surfactant
phospholipids [9].
Pulmonary surfactant is composed by 90% lipids,
mostly phospholipids, and 10% of specific proteins [10].
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tein synthesized as a preprotein (pro-SP-B) and pro-
cessed to mature form en route from the Golgi complex
to the lamellar bodies [11]. Mature SP-B is secreted as a
surfactant component into the alveolar space where it is
mainly found as a dimer [12]. Clara cells also express
pro-SP-B, but they do not process the protein to the
mature form [13]. SP-B enhances the rate of phospholi-
pid adsorption to the alveolar air/water interface [14],
decreases surface tension by interfering with the attrac-
tive forces acting between water molecules [15] and has
anti-inflammatory properties [2,3].
Clinical studies have shown that disaturated-phospha-
tidylcholine (DSPC) is markedly decreased in bronchoal-
veolar lavage fluid of adult ARDS patients, whereas the
phosphatidylcholine content is only slightly decreased
[2,3]. SP-B has also been reported to be reduced by
25-55% in tracheal aspirates of adult ARDS/ALI patients
[2,6] but in association with normal levels of SP-B
mRNA [16]. Conversely a recent study performed in
children confirmed a significant decrease of DSPC but
no significant changes in SP-B levels in bronchoalveolar
lavage fluid of ALI/ARDS children compared with con-
trols [17]. Decreased levels of DSPC and SP-B could be
due to increased degradation, decreased synthesis or
both. The goal of this investigation was to measure the
rate of synthesis of DSPC and SP-B in ARDS/ALI
patients and in controls with normal lungs.
Methods
Patients were studied from 2003 to 2006. ARDS and
ALI cases were defined by the AECC criteria [1]. Twelve
patients were recruited within 72 hours from the onset
of the respiratory failure. Causes of ARDS/ALI were
pneumonia in 6 patients, polytrauma in 4, pancreatitis
in 1 and aspiration of gastric contents in 1. Eight
patients without lung disease, who needed mechanical
ventilation after major surgery or for neurological fail-
ure, were enrolled as controls. Exclusion criteria were:
presence of liver failure, defined as transaminases (GOT,
GPT) >3 times normal values, renal failure (creatinine
>2 times normal values), burns >30% body surface area,
bone marrow or lung transplantation. The local ethical
committee approved the study, and informed consent
was obtained for all the patients.
Clinical data, ventilator parameters, arterial blood gas
analysis and trascutaneous saturation were recordered at
the start of the study and then every 6 hours during the
study period. Routine blood tests performed at the
admission to the ICU and during the study according to
the standard unit practice were also recorded in order
to detect signs of nosocomial infection or of organ fail-
ure. For each patient SAPSII score was calculated at
study entry.
Methods and study design
All patients received a constant intravenous infusion of
1g1 -
13C Leucine (Cambridge Isotope Laboratories,
Andover, MA) dissolved in saline for 24 h.
2H2O
(Cambridge Isotope Laboratories, Andover, MA) was
administered as a 25 ml bolus at the study start and
then, every 12 hours over the next 36 hours, as intermit-
tent boluses corresponding to 0.0625% of fluid intake, to
maintain steady state of deuterium enrichment in body
water [18].
Blood (0.6 ml), urine (1 ml) and tracheal aspirates [19]
were collected at times 0, 6, 12, 18, 24, 30, 36, 42,
48 hours and then every 12 hours until extubation. Tra-
cheal aspirates and blood samples were centrifuged at
400 g and 1300 g respectively and supernatants were
stored at -80°C.
Tracheal aspirates protein and phopholipid analysis
Total proteins from tracheal aspirates were determined
at time 0 or within the first 24 hours [20]. Phospholipid
phosphorous was measured in tracheal aspirate samples
till 48 hours [21] from the start of the study.
DSPC was extracted and separated from tracheal aspi-
rates according to standard methods [22] and DSPC
fatty acids derivatized as methyl-esters and measured by
gas chromatography [19].
SP-B amounts were quantified by ELISA on unfractio-
nated tracheal aspirates obtained at the beginning of the
study or within 24 hours [23] using a rabbit antiserum
directed against mature SP-B [24].
DSPC, SP-B and protein concentrations in aspirates,
were normalized to alveolar lining fluid using the urea
method (BioAssay Systems, Hayward, CA) [25].
Isolation of SP-B from tracheal aspirates
SP-B was isolated from tracheal aspirates and hydro-
lyzed as previously published [26]. Briefly, SP-B was iso-
lated from lipid extract with Bond Elute NH2 containing
100 mg resin (Supelco, Milano, Italy) preconditioned
with 3-5 ml of chloroform. After loading the sample, the
columns were eluted sequentially with 3 ml of the fol-
lowing chloroform/methanol/acetic acid mixtures:
20:1:0; 9:1:0; 4:1:0; 4:1:0.025; 3:2:0; 1:4:0; 1:9:0. SP-B frac-
tion (4:1:0 and 4:1:0.025) were pooled together, dried
under nitrogen and hydrolysed to free amino acids by
0.5 ml of HCl 6 N for 24 h at 110°C. Individual amino
acids were derivatized into their N-acetyl-n-propyl deri-
vatives [27] and the
13C enrichment of leucine measured
by mass spectrometry (GC-MS Voyager, Thermoquest,
Milan, Italy).
Plasma leucine enrichment
One hundred μl of plasma were deproteinized with sul-
phosalicilic acid (6% w/v) and plasma amino acids were
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enrichment was measured by gas chromatography mass
spectrometry. Results were expressed as Mole Percent
Excess with reference to a calibration curve for 1-
13C
Leucine.
Urine deuterium enrichment
One hundred μl of urine were deproteinized with sul-
phosalicilic acid (6% w/v) and diluted 1:10 with local
distilled reference water. Urine deuterium enrichment
was analysed by a High Temperature Conversion Ele-
mental Analyser coupled with an Isotope Ratio-Mass
Spectrometer (TC-EA-IRMS, Thermo Scientific,
Bremen, Germany) [29]. Enrichment was expressed as
delta ‰.
The
2H enrichment of DSPC-palmitate was analyzed
by gas chromatography-IRMS and expressed in delta ‰
after correction for isotopic contribution of the deriva-
tive group [18].
Calculations
All kinetic measurements were performed assuming a
steady state. The assumption was based on the following
considerations: 1) in all patients plasma 1
13Cl e u c i n e
and urine
2H2O enrichments reached steady state within
6 h from the start of the isotope infusion; 2) the slope
of the enrichment curve over time did not deviate sig-
nificantly from zero between time 6 h and time 24 h for
plasma leucine and between time 6 h and time 36 h for
urine
2H2O; 3) the concentrations of DSPC and SP-B in
tracheal aspirates did not change significantly during the
first 48 hours of the study.
Tissue-bound and alveolar surfactant was regarded as
one pool. The fractional synthesis rate was calculated as
previously reported [18,19].
Clinical and kinetic variables were expressed as mean
± SD or median (interquartile range) as appropriate.
Statistical analysis was performed by a non-parametric
test (Mann-Whitney test). Significance was defined as
p < 0.05. Data were analysed using the statistical pack-
age SPSS 15 (SPSS Inc, Chicago, IL).
Results
Clinical characteristics
Twelve ARDS/ALI and 8 control adults were studied.
Clinical characteristics and ventilator parameters are
reported in Table 1. Only 4 of the 8 controls were on
mechanical ventilation, the remaining patients were on
spontaneous breathing through a tracheostomy. All
ARDS/ALI patients exhibited severe derangement of gas
exchange at the time of the study start (which corre-
s p o n d e dt ot h ef i r s tt r a c h e a la s p i r a t ec o l l e c t i o n )w i t ha
PaO2/FiO2 ratio of 185 ± 61. Thereafter PaO2/FiO2
values progressively improved, but remained markedly
lower than control values (Table 1). Two of the 20
patients (both with ARDS) died within 30 days from the
study start.
Surfactant composition
Total proteins, total phospholipids, DSPC and SP-B con-
centrations, normalized to epithelial lining fluid, at study
start are shown in Table 2. In patients with ARDS/ALI
total protein concentration were higher, (p < 0.05), total
phospholipids were not different, and DSPC and SP-B
were markedly and significantly lower than in controls.
DSPC and SP-B concentrations were 16.9% and 40.5%
of the control values respectively.
DSPC, as percentage of total phospholipids, was lower
in ARDS/ALI than in controls throughout the study
(p < 0.01).
Surfactant DSPC and SP-B kinetics
DSPC concentration in tracheal aspirates was measured
every 6 hours for the first 48 hours in all ARDS/ALI
patients to assess the steady state of the surfactant pool.
Except for 1 ARDS patient, who was excluded from the
study for an increasing DSPC concentration over time,
all patients had DSPC concentration within 10% of coef-
ficient of variation (data not shown), suggesting a steady
state condition during the time frame of kinetics mea-
surement. Enrichment curves of DSPC-palmitate and
SP-B-leucine from ARDS patients and control subjects
are shown in Figure 1. In most subjects SP-B enrich-
ments returned to baseline within 60 hours from the
start of the tracer infusion, while DSPC enrichments
took about 150-200 hours to return to baseline.
SP-B turned over at a much faster rate than DSPC both
in controls and in patients with ARDS/ALI (Figure 1). In
controls SP-B turned over at a rate 28 times faster than
DSPC.
In ALI/ARDS the fractional synthesis rate of DSPC
was 3.1 times higher than in controls (p < 0.01), while
the fractional synthesis rate of SP-B was not statistically
different than in control subjects (Figure 2).
Discussion
This paper provides novel information on the turnover
of DSPC and SP-B in normal subjects and in patients
with ARDS/ALI, while confirming that patients with
ARDS/ALI have decreased levels of DSPC and SP-B and
increased protein concentration in tracheal aspirates
[2,4-6,16,30,31].
In agreement with previous animal studies [24,32], we
f o u n dt h a tS P - Bi st u r n e do v e ra taf a s t e rr a t et h a n
DSPC both in controls and in ARDS/ALI. Since SP-B
and DSPC are packaged into lamellar bodies and then
are secreted together, their different turnover rate could
be explained by partitioning into distinctive alveolar
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the interfacial film or stay there for a longer time), by
an intrinsically faster turnover of SP-B in the alveolar
space or by the use of different pathways of recycling
before packaging into lamellar body membranes.
Human studies do not allow to further discriminate
among these possibilities, since lung tissue could not be
sampled. From animal experiments, though, we can
extrapolate that all these mechanisms could be at play
[24,32].
I nt h ep r e s e n ts t u d yw eu s e d
2H2O as metabolic pre-
cursor for DSPC synthesis. This is at variance from
other studies by our group where we used other meta-
bolic precursors, such as deuterated palmitate or unifor-
mely labeled
13C glucose [18,33,34]. We chose the heavy
water for its ease to use and because in preterm and
term infants we found that heavy water gives estimates
of DSPC synthesis similar to those obtained using other
metabolic precursors [34]. ARDS/ALI patients showed
an increased synthesis rate of DSPC but not of SP-B. If
the increased synthesis rate of DSPC seems a logical
compensatory mechanism to increased phospholipid
degradation or monolayer inactivation in the injured
lungs, the finding that in ARDS/ALI the rate of synth-
esis of SP-B is comparable to control subjects, is unex-
pected. Possible explanations are that ARDS/ALI
patients cannot mount a compensatory enhanced synth-
esis of SP-B or conversely that the decrease of airway
SP-B in our ARDS patients was not big enough to elicit
a homeostatic response. In agreement with the last
interpretation, a recent study with a transgenic mouse
model expressing human TNF-a in respiratory epithelial
cells showed that, after a 36-61% decrease of airway SP-
B, the level of SP-B mRNA in lung tissue remained
unchanged [16].
Differently from SP-B, the lung appeared to “sense”
the larger decrease in airway DSPC content and
increased three fold its fractional rate of synthesis. The
mechanism underlying this response remains unclear.
A recent article investigating the role of signal transdu-
cer and activator of transcription-3 (STAT-3), which is
activated by members of IL-6-like group of proinflam-
matory cytokines [35], found that in mice treated with
Table 1 Clinical characteristics and ventilator parameters of study patients
VARIABLE PATIENTS p
ARDS/ALI (N = 11) CONTROL (N = 8)
Male/Female (n°) 6/5 4/4
Age (y) 53 ± 16 48 ± 24 0.66
Body weight (Kg) 80 ± 16 69 ± 19 0.21
Survival 82% 100%
SAPS II 37 ± 12 37 ± 5 0.46
PIP at the start of the study (cm H2O) 25 ± 6 14 ± 4 (4/8) <0.01
PIP during the study (cm H2O) 24 ± 6 14 ± 4 (4/8) 0.05
PEEP at the start of the study (cm H2O) 9 ± 2 3 ± 1 (4/8) <0.01
PEEP during the study (cm H2O) 9 ± 2 3 ± 0.4 (4/8) <0.01
PaO2/FiO2 at the start of the study 185 ± 61 365 ± 72 <0.001
PaO2/FiO2 during the study period 208 ± 46 383 ± 82 <0.001
AaDO2 at the start of the study (mmHg) 309 ± 111 71 ± 27 <0.001
AaDO2 during the study (mmHg) 255 ± 84 74 ± 41 <0.001
Tidal Volume (ml/Kg bw) 7 ± 1 7 ± 1 (4/8) 0.54
Clinical characteristics and ventilatory parameters of study patients. Mean ± SD. PaO2/FiO2 = mean oxygen tension in arterial blood/inspiratory oxygen fraction.
PEEP = positive end expiratory pressure. PIP = peak inspiratory pressure. AaDO2 = Alveolar arterial oxygen gradient. APACHE II = scores on the acute physiology
and chronic health evaluation. Values compared with Mann-Whitney test.
Table 2 Surfactant composition of tracheal aspirates
VARIABLE PATIENTS p
ARDS/ALI CONTROLS
Total phospholipids
(mg/ml ELF)
0.98 (0.57-1.30) 2.30 (1.03-1.66) 0.07
Total protein
(mg/ml ELF)
68.6 (46.3-97.2) 44.7 (33.7-49.1) <0.05
PPQ 0.010 (0.014-0.036) 0.034 (0.024-0.051) <0.01
SP-B (μg/ml ELF) 1.7 (0.8-2.9) 4.2 (3.4-5.8) <0.05
SP-B (%PL) 0.21 (0.08-0.36) 0.21 (0.11-0.44) 0.7
DSPC (mg/ml ELF) 0.11 (0.08-0.24) 0.65 (0.50-2.59) <0.01
Mean DSPC (%PL) 50 (43-51) 54 (52-58) <0.01
All data represent as median and interquartile range. PPQ = Phospholipid-to-
Protein quotient. ELF = epithelial lining fluid. Total protein, total
phospholipids, DSPC and SP-B were determined in one tracheal aspirates at
the start of the study or within 24 h. Values were corrected for dilution using
the urea method. DSPC (%PL) was determined in all tracheal aspirates
collected till the end of the study. Values were compared using Mann-
Whitney test.
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STAT-3 dependent way [36].
I nt h i ss t u d yw eh a v em e a s u r e da l s oD S P Ca n dS P - B
concentration in epithelial lining fluid as a proxy of sur-
factant pool. The estimation of airway surfactant pool by
the measurement of individual surfactant components
obtained from tracheal aspirates has limitations, since the
recovery may vary, in spite of the standardization of the
suction technique and the correction for dilution. There-
fore the low concentrations of DSPC and SP-B recovered
from tracheal aspirates of patients with ARDS/ALI could
be due either to decreased surfactant concentration in
Figure 1 SP-B leucine and DSPC-palmitate enrichment curves in ARDS/ALI and in control patients.T h e
13C-leucine (top panels) and
deuterium-palmitate (bottom panels) enrichment curves of SP-B and DSPC obtained from tracheal aspirates. Each symbol represents a different
subject. MPE: mole percent excess; Delta (
2H/
1H vs smow).
Figure 2 Fractional synthetic rate of DSPC-palmitate and SP-B-leucine in ARDS/ALI and control patients. Synthesis of DSPC-palmitate
results to be significantly higher in ARDS/ALI group. SP-B-leucine synthesis is similar in the two groups. Results are expressed as median and
interquartile ranges. * Significantly different from controls (p < 0.01 by Mann-Whitney test).
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prone to release surfactant recoverable by aspiration or
even to the sampling technique that could be affected by
clinical severity. These observations can partially explain
the controversial results reported on surfactant SP-B
amount during ARDS/ALI [2,6,17].
Kinetic data obtained from tracer studies have the
advantage of being independent from recovery. Tracer
studies were classically performed in animals using
radioactive tracers, and they showed that surfactant spe-
cific proteins A, B and C were turned over faster than
DSPC [24,32]. Using stable isotopes we can now per-
form kinetic studies in humans and even in preterm
infants. By this approach we previously measured the
rate of synthesis of DSPC and SP-B in newborn infants
with and without respiratory failure [18,26]. Further-
more, by administering DSPC labelled with stable iso-
topes through the airways, we showed that in a
population of patients with ARDS the airway DSPC pool
was 10 fold smaller than in controls [37].
A further limit on the estimation of the airway surfac-
tant composition and pool by tracheal aspirates derives
f r o mt h ef a c tt h a tt h ec u r r e n t l ya v a i l a b l eE L I S Am e t h -
ods to measure SP-B cannot distinguish between the
mature protein and its pro-forms, nor do they recognize
modified SP-B, like oxidized SP-B, whose possible
pathogenetic role has been recently underlined [38]. In
this paper we separated mature SP-B by sorbent chro-
matography and thus provides kinetic data regarding
solely mature SP-B.
Since the concentrations of DSPC and SP-B in the tra-
cheal aspirates of patients with ARDS/ALI did not
change significantly duringt h es a m p l i n gp e r i o d ,w e
assumed that patients were at steady state, with synth-
esis matching degradation for both surfactant compo-
nents. However, due to the uncertainty about the true
dimensions of the alveolar pool of DSPC and SP-B, the
present data did not allow us to calculate the absolute
rate of synthesis of these compounds [39].
In conclusion our paper provides original data on
DSPC and SP-B turnover “in vivo“ in humans. Our
results can be summarized as follows: 1) DSPC and
SP-B turned over with different kinetics in the airways
both in human adults with normal lungs and in
patients with ARDS/ALI, 2) in patients with ARDS/
ALI in spite of the low concentration of DSPC and SP-
B in tracheal aspirates, the fractional synthesis rate of
DSPC increased, while that of SP-B did not change
significantly.
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